玻璃体腔注射Bevacizumab治疗视网膜分支静脉阻塞性黄斑水肿(英文)

目的:观察玻璃体腔注射bevacizumab(Avastin)治疗视网膜分支静脉阻塞性黄斑水肿的有效性和安全性。方法:观察一组视网膜分支静脉阻塞引起黄斑水肿的连续病例,对其进行玻璃体腔注射bevacizumab(Avastin)后的疗效进行分析。所有患者在治疗开始前以及治疗后随诊时间点均进行完全的眼科相关检查,包括视力测定,OCT和/或FFA检查。结果:对32例患者(32眼)分别至少进行一次玻璃体腔注药(1～3次),术后平均观察时间为4.7mo。平均视力:治疗前为20/200-,治疗后1mo20/100-,治疗后3mo及最近一次检查为20/100+(P<0.01);黄斑中心1mm区厚度:治疗前为483μm,治疗后1,3mo及最近一次分别为275,314和301μm(P<0.01)。没有观察到任何不良副作用。结论:玻璃体腔注射bvacizumab(Avastin)治疗能显著减轻视网膜分支静脉阻塞性黄斑水肿、提高视力且没有不良反应。

Intravitreal bevacizumab (Avastin) treatment of macular edema in branch retinal vein occlusion

AIM:To report the safty and efficiency of intravitreal injection of bevacizumab (Avastin) in patients with macular edema (ME) due to branch retinal vein occlusion (BRVO).METHODS: A consecutive series of patients with ME due to BRVO who were treated with intravitreal bevacizumab injection (2.5g/0.1L) were retrospectively studied. Patients underwent complete ophthalmoscopic examination, including Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and/or flurescence angiographic testing at baseline and follow-up visits.RESULTS: There were 32 eyes of 32 consecutive patients who received at least one intravitreal bevacizumab injections (range from 1 to 3). The mean length of follow-up was 4.7 (range from 3 to 8) months. The mean visual acuity improved from 20/200- at baseline to 20/100- at 1 month and 20/100+ at 3 months and last follow-up (P＜0.01). The mean central 1mm macular thickness was 483μm at baseline and decreased to 275, 314,and 301μm at 1 month,3 months, and last follow-up (P＜0.01)respectively.No adverse side effects were observed following injections in any eyes.CONCLUSION: Intravitreal bevacizumab (Avastin) showed a marked decrease in ME secondary to BRVO, improvement in visual acuity and lack of adverse side effects.